Page 1192 - Basic _ Clinical Pharmacology ( PDFDrive )
P. 1192

All adults; pregnant women should receive a dose with each

                              pregnancy (preferred during 27–36 weeks of gestation)







                                  Risk of exposure to typhoid fever  Risk of exposure to typhoid fever    Persons past their 13th birthday without a history of varicella infection  Postexposure prophylaxis in susceptible persons Laboratory personnel who may be exposed to yellow fever virus Travelers to areas where yellow fever occurs  All adults ≥60 years of age







                         Indications          For all children  1.   2.   or immunization  3.   1.   2.

                  Materials commonly used for active immunization in the United States. 1  (Continued)





                         Booster 2  None  Four doses every   5 years  Every 2 years  Unknown  Every 10 years  None 3 Three Hib conjugate vaccines are available for use: (1) oligosaccharide conjugate Hib vaccine (HbOC), (2) polyribosylribitol phosphate-tetanus toxoid conjugate (PRP-T), and (3) Haemophilus influenzae type b conjugate vaccine  4 Three HPV vaccines are available for use: (1) quadrivalent vaccine (HPV4) and (2) 9-valent vaccine (HPV9) for the prevention of cervical, vaginal, and vulvar cancers (in females) and genital warts (i








                         Primary Immunization  Substitute one dose of Tdap for Td   in all adults  Four doses administered every   other day  One dose  Two doses 4–8 weeks apart in  persons past their 13th birthday  (see Table A–2 for childhood   schedule)  One dose 10 years to 10 days   before travel  One dose













                       Route of   Administration  Intramuscular  Oral  Intramuscular  Subcutaneous  Subcutaneous  Subcutaneous 1 Dosages for the specific product, including variations for age, are best obtained from the manufacturer’s package insert.





                         Type of Agent  Toxoids and inac-  tivated bacterial   components  Live bacteria  Bacterial   polysaccharide  Live virus  Live virus  Live virus  (meningococcal protein conjugate) (PRP-OMP). vaccine (HPV2) for the prevention of cervical cancers in females.






                  TABLE A–1   Vaccine  Tetanus, diph-  theria, pertussis   (Tdap)  Typhoid, Ty21a   oral  Typhoid,   Vi capsular   polysaccharide  Varicella  Yellow fever  Zoster  2 One dose unless otherwise indicated.  toxoid as DPT).







                 1178
   1187   1188   1189   1190   1191   1192   1193   1194   1195   1196   1197